The "Neoantigen Cancer Vaccine Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering.

The neoantigen cancer vaccine market is rapidly redefining standards in immuno-oncology by enabling patient-specific treatments that enhance therapy precision and minimize systemic side effects for oncology stakeholders.

Market Snapshot: Neoantigen Cancer Vaccine Market

The Neoantigen Cancer Vaccine Market grew from USD 378.66 million in 2024 to USD 434.55 million in 2025. It is expected to continue growing at a CAGR of 15.40%, reaching USD 1.19 billion by 2032. Market expansion is supported by advances in genomic profiling, immunotherapy, and streamlined manufacturing capabilities. The landscape is driven by robust clinical adoption, increased research investments, and favorable regulatory momentum for innovative, personalized cancer therapies. Competitive activity and international partnerships are further accelerating uptake and market maturity in strategic regions.

Scope & Segmentation Analysis

This report offers a granular overview of the neoantigen cancer vaccine landscape, delivering critical segmentation insights across therapy design, administration, and market participants. Segmentation facilitates a comprehensive understanding of evolving strategies and commercialization routes. The following key segments are covered:

• Neoantigen Type: Personalized neoantigens (including immune escape mutations and somatic mutations) and shared neoantigens (encompassing affinity peptides and common tumor mutations).
• Therapeutic Target: Immune checkpoint blockades (CTLA-4 inhibitors, PD-1 inhibitors) and tumor neoantigens (mutated and non-mutated variations).
• Vaccine Platform: Cell-based vaccines (dendritic cell, T-cell), DNA-based vaccines (circular DNA platforms, plasmid DNA), peptide-based vaccines (long and synthetic peptides), and RNA-based vaccines (mRNA, next-gen RNA platforms).
• Administration Route: Intradermal, intravenous, oral, and subcutaneous delivery methods.
• End User: Cancer treatment centers, hospitals, and research institutes.
• Regions: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, UAE, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan).
• Key Players: Companies such as Agenus Inc., AstraZeneca PLC, BioNTech SE, Moderna, Inc., Merck & Co., Inc., Takis S.r.l., CureVac N.V., and others active in advanced oncology research and commercialization.

Key Takeaways for Senior Decision-Makers

• Neoantigen cancer vaccines are reshaping oncology therapy by exploiting patient- and tumor-specific antigenic profiles, enabling highly targeted, durable anti-tumor responses.
• Substantial advances in next-generation sequencing and machine learning-based epitope identification are increasing the speed, reliability, and precision of vaccine design and patient matching.
• Stakeholders are strengthening supply chain resilience through diversification strategies, improved inventory management, and enhanced forecasting, critical for pandemic-readiness and evolving regulatory requirements.
• Collaborative R&D models unite academia, biotech startups, and large pharma, accelerating translational research, clinical validation, and streamlined manufacturing scale-up.
• Diversified vaccine platform technologies-ranging from cell-based to nucleic acid-based modalities-enable sponsors to tailor product profiles to address specific cancer types, patient subgroups, and clinical settings.

Why This Report Matters

• Provides actionable segmentation analysis to help prioritize R&D, clinical strategy, and commercialization plans in alignment with market opportunities.
• Equips senior management with a clear view of evolving regulatory and supply chain dynamics, supporting proactive risk management and investment planning.
• Delivers competitive intelligence on leading platforms, partnering strategies, and innovation drivers shaping near- and mid-term outcomes.

Key Attributes

Market Insights

• Integration of AI-driven neoantigen identification platforms to enhance personalized vaccine design
• Adoption of multiplexed immunopeptidomics to improve neoantigen discovery accuracy in trials
• Emergence of mRNA-based neoantigen vaccine platforms advancing rapid manufacturing timelines
• Collaboration between biotech and academic centers to accelerate neoantigen clinical validation processes
• Increasing investment in personalized neoantigen vaccine programs targeting melanoma and lung cancer
• Focus on combining neoantigen vaccines with checkpoint inhibitors to boost therapeutic efficacy in solid tumors

The companies profiled in this Neoantigen Cancer Vaccine market report include:

• Agenus Inc.
• AstraZeneca PLC
• Avidea Technologies
• Ayala Pharmaceuticals, Inc.
• BioLineRx Ltd.
• BioNTech SE
• BioVaxys Technology Corp.
• Brightpath Biotherapeutics Co., Ltd.
• CureVac N.V.
• Elicio Therapeutics Inc
• F. Hoffmann-La Roche Ltd.
• Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
• Genocea Biosciences Inc
• GenScript Biotech Corporation
• Gilead Sciences, Inc.
• Gritstone bio, Inc.
• Immunomic Therapeutics, Inc.
• ISA Pharmaceuticals B.V.
• Medigene AG
• Merck & Co., Inc.
• Moderna, Inc.
• Neophore Limited
• Nouscom AG
• Nykode Therapeutics ASA
• OSE Immunotherapeutics
• Takis S.r.l.

For more information about this report visit https://www.researchandmarkets.com/r/7n2gu0

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251211506827/en/